Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Lasa Supergenerics Ltd

₹ 11.55.62%
06 Jan – close price
🔗lasalabs.com•BSE: 540702•NSE: LASA
Market Cap₹ 57.5 Cr.
Current Price₹ 11.5
High / Low₹ 30.0
Stock P/E120
Book Value₹ 11.2
Dividend Yield0.00 %
ROCE-1.00 %
ROE1.01 %
Face Value₹ 10.0
Sales₹ 95.3 Cr.
OPM-0.86 %
Mar Cap₹ 57.5 Cr.

ABOUT

Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]

KEY POINTS

Business Overview:[1]LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production

Also present in buckets:
Red Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1760.2036.58422330.940.913124.952.5614478.318.9320.2154964.0130.1211543.963117.955.4312.970.07
2.Divi's Lab.6642.5070.96176337.500.45689.0035.102715.0016.1220.4410029.0032.372485.00689.0011.4413.530.01
3.Torrent Pharma.3936.8061.50133239.200.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1715.7713.260.33
4.Cipla1530.8022.73123653.620.851353.373.737589.447.6422.7228349.5725.405441.141351.173.7614.720.01
5.Dr Reddy's Labs1256.2018.16104846.270.641336.807.288828.309.8322.6934310.0024.645772.201347.102.9112.950.16
6.Lupin2149.7022.7198198.040.561484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0012.410.32
7.Zydus Lifesci.931.0518.6393685.421.181238.6040.926123.2016.9224.3124493.9031.105029.351283.603.7014.640.38
8.Lasa Supergeneri11.47119.7357.470.00-6.25-93.503.06-92.23-1.0095.29-0.860.48-6.251.020.720.13
–Median: 151 Co.405.7530.681679.940.1112.5711.71152.6410.5814.89574.0115.9343.8413.493.118.560.22

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
31.7026.6633.0830.5630.8420.0135.3222.8239.1433.6624.3039.393.06
Expenses
34.1625.6032.8126.5129.0420.5130.9826.8135.7333.9923.2538.607.06
Operating Profit
-2.461.060.274.051.80-0.504.34-3.993.41-0.331.050.79-4.00
Other Income
0.860.008.910.000.00-20.44-18.97-8.76-21.52-2.470.081.950.01
Profit before tax
-5.12-2.065.911.03-1.86-22.54-19.21-15.97-22.12-6.73-2.11-1.31-5.68
Tax %
-3.91%-29.61%7.11%580.58%46.77%-6.30%-21.92%-4.20%-35.40%-2.08%-99.05%146.56%10.04%
Net Profit
-4.92-1.465.49-4.95-2.73-21.12-15.00-15.30-14.29-6.61-0.02-3.23-6.25
EPS in Rs
-1.21-0.291.10-0.99-0.54-4.22-2.99-3.05-2.85-1.63-0.00-0.64-1.25

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
019924417016720113713010414295
Expenses
015320215813715412013610213696
Operating Profit
0464111304716-626-1
Other Income
0-243000-8-18-9-11-33
Interest
0121188204231
Depreciation
08181917161513111210
Profit before tax
0215-16530-6-42-19-19-44
Net Profit
0212-12423-5-39-22-15-36
EPS in Rs
––5.40-5.260.895.60-1.31-7.71-4.34-2.95-7.22
Dividend Payout %
–0%0%0%0%4%-24%0%0%0%–

Compounded Profit Growth

10 Years:%
5 Years:-25%
3 Years:-28%
TTM:103%

Compounded Sales Growth

10 Years:%
5 Years:-3%
3 Years:1%
TTM:-20%

Return on Equity

10 Years:%
5 Years:-1%
3 Years:-10%
Last Year:1%

Stock Price CAGR

10 Years:%
5 Years:-34%
3 Years:-26%
1 Year:-60%

Balance Sheet

Standalone figures in ₹ crores

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
0.050.05232341415050505050
Reserves
07594821011181086847346
Borrowings
011610785481920222227
Other Liabilities
03763694229312432168
Total Liabilities
022828725823220820916415110272
Fixed Assets
01191701621521431371191106858
Gross Block
0.00131.61200.58211.87219.54226.12233.77228.70230.18––
Accumulated Depreciation
0.0012.7830.9450.1767.3583.1796.49109.74120.42––
CWIP
030770055300
Investments
00000000000
Other Assets
0801109080656740393313
Total Assets
022828725823220820916415110272

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
0-3404114419-172-3
Cash from Investing Activity
00-44-7-2-4-311-08
Cash from Financing Activity
004-33-10-36-0-4-2-6
Net Cash Flow
0-30-0216-10-0-0

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
–6463624527507134
Inventory Days
–9390901015646489284
Days Payable
–711021701304168326835
Cash Conversion Cycle
–8751-18164228223753
Working Capital Days
–15-1-52-133512-17-4437
ROCE %
–42%13%-4%7%17%1%-12%-6%-1%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
43.78%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%
FIIs
0.00%0.00%0.00%0.00%0.01%0.12%0.00%0.01%0.00%0.00%0.47%0.00%
DIIs
––––––––––––
Public
56.21%46.34%46.34%46.34%46.33%46.23%46.34%46.32%46.35%46.35%45.88%46.35%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

LASA Supergen Declares Non-Applicability of SEBI Large Corporate Framework

16th April 2026, 10:18 pm

LASA Supergenics to Close Trading Window From April 1, 2026

30th March 2026, 11:19 pm

Financial Results Roundup: Lasa Supergenics Faces Fire Impact, Multiple Companies Announce Q3 FY26 Performance

15th February 2026, 12:54 am

Q3 FY26 Results: Lasa Supergenics Suffers Production Halt Due to Fire; Other Firms Announce Financial Updates

14th February 2026, 5:39 pm

Lasa Supergenerics Files Q3 Results Amidst Production Halt, Uninsured Losses, and Going Concern Doubts

13th February 2026, 9:23 pm

Published by Other Websites

External media mentions & references

Stocks Under ₹100 Surge! Top Gainers Emerge as Indian Markets Hit New Highs

2nd January 2026, 5:06 pm

Buyers Flock to Penny Stocks! Rs 100 Shares Surge in Upper Circuit Frenzy

1st January 2026, 4:37 pm

Indian Stock Market Trades Higher, Sensex and Nifty-50 Reach New 52-Week Highs

9th September 2025, 4:11 pm

News Articles

Editorial & research coverage

Buyers Flock to Penny Stocks! Rs 100 Shares Surge in Upper Circuit Frenzy
Buyers Flock to Penny Stocks! Rs 100 Shares Surge in Upper Circuit Frenzy

1st January 2026, 4:37 pm

Documents

Announcements

Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. January 02, 2026 1. Appointment Of Mr. Ganesh Suresh Potdar As An Additional Director In Capacity Of (Executive Director) And Occupier Of All Units Of The Company.

2 Jan - Appointed Ganesh Suresh Potdar as Executive Director/Occupier, effective Jan 02, 2026; term to Jan 01, 2030, subject to shareholder approval.

Closure of Trading Window

29 Dec - Trading window closed Jan 01, 2026 until 48 hours after unaudited results for quarter ended Dec 31, 2025.

Appointment of Company Secretary and Compliance Officer

15 Dec - Appointed Mrs. Mitti Jain as Company Secretary, Compliance Officer and KMP effective December 16, 2025.

Announcement under Regulation 30 (LODR)-Cessation

11 Dec - Whole-time Director Prathmesh Chalke resigns effective closing hours 31 December 2025; resignation dated 11 December 2025.

Related Party Trasnaction As 30.09.2025

14 Nov 2025 - Related-party transaction disclosure for quarter/half-year ended Sep 30, 2025; lists payments (total 710) and donations (28.50).

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Credit Ratings

No credit ratings.

Concalls

Aug 2021

Transcript

Feb 2021

Transcript

Oct 2020

PPT

Jun 2020

TranscriptPPT

Jun 2018

TranscriptPPT

Feb 2018

PPT

Dec 2017

TranscriptPPT

Stock Analysis

Description

  1. Lasa Supergenics Limited operates in the pharmaceutical sector, focusing on manufacturing and trading Active Pharmaceutical Ingredients (APIs) and related chemicals, primarily for veterinary use. The company has faced significant operational setbacks.

Key Growth Triggers

  1. Currently no data available for Key Growth Triggers.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Severe operational disruption due to a major fire incident in May 2025, resulting in uninsured losses and a complete halt in production.
  2. Significant increase in net losses for H1 FY26 and a sharp year-on-year decline in total assets.
  3. Auditor's report explicitly flags substantial going concern issues, indicating doubts about the company's ability to continue operations.
  4. Multiple director resignations citing the company's non-operational status and lack of active business.

Key Dates To Watch

  1. Board meetings to approve future financial results, including for the quarter ended December 31, 2025, and subsequent quarters.
  2. Shareholder approvals for appointments and strategic decisions related to operational continuity.

Corporate Announcements

16th Apr 26
Impact Rating: 5
LASA Supergen Limited has submitted a declaration to BSE and NSE stating that it is not classified as a 'Large Corporate' according to SEBI circular number SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which pertains to debt securities issuance.
30th Mar 26
Impact Rating: 5
LASA Supergenics Limited will close its trading window for designated employees and their relatives effective April 1, 2026. The window will remain shut until 48 hours after the announcement of its audited financial results for FY26.
14th Feb 26
Impact Rating: -
No description available.
14th Feb 26
Impact Rating: -
No description available.
13th Feb 26
Impact Rating: 9
Lasa Supergenerics Limited announced the filing of its Unaudited Financial Results for the quarter ended December 31, 2025. The accompanying auditor's limited review report details a significant fire incident causing uninsured losses, operational shutdown, and potential going concern uncertainties, impacting future operations.